---
title: "Konruns: KC1036 included in the Drug Review Center's \"Starlight Program\" pilot project"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/256078414.md"
description: "Konruns announced that its Class 1 innovative drug KC1036 has been included in the \"Starlight Program\" of the National Medical Products Administration's Drug Evaluation Center. KC1036 is an anti-tumor drug independently developed by the company, which has shown good safety and anti-tumor activity in multiple clinical studies. This selection marks the Drug Evaluation Center's recognition of its innovation and potential benefits for adolescent patients with Ewing's sarcoma. Konruns will continue to advance the research and market launch of this drug in the field of pediatric oncology"
datetime: "2025-09-05T07:42:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/256078414.md)
  - [en](https://longbridge.com/en/news/256078414.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/256078414.md)
---

# Konruns: KC1036 included in the Drug Review Center's "Starlight Program" pilot project

According to the Zhitong Finance APP, Konruns (603590.SH) announced that its Class 1 innovative drug KC1036 has recently been included in the "Pilot Program for the Development of Antitumor Drugs for Children (Starlight Program)" by the National Medical Products Administration's Drug Evaluation Center (referred to as "Drug Evaluation Center").

KC1036 is a Class 1 innovative chemical drug independently developed by the company, and the company holds global intellectual property rights for this product. KC1036 achieves antitumor activity by inhibiting multiple targets such as VEGFR2 and AXL. Currently, KC1036 has initiated multiple Phase I to III clinical studies, with over 300 adult cancer patients having received KC1036 treatment, demonstrating outstanding antitumor activity, as well as good safety and tolerability in various indications, including gastrointestinal tumors and thymic tumors.

As one of the first innovative drug varieties selected for the "Starlight Program," KC1036 represents the Drug Evaluation Center's recognition of its innovation and its potential benefits for adolescent patients with Ewing's sarcoma, further promoting the company's focus on the clinical needs of pediatric cancer patients in China. The company will actively report progress or results related to the implementation framework required by the Drug Evaluation Center to jointly advance the clinical research and market launch of KC1036 in the field of pediatric Ewing's sarcoma

### Related Stocks

- [603590.CN](https://longbridge.com/en/quote/603590.CN.md)

## Related News & Research

- [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md)
- [Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants | ANVS Stock News](https://longbridge.com/en/news/286960443.md)
- [NYC Health and Hospitals says hackers stole medical data and fingerprints during breach affecting at least 1.8 million people](https://longbridge.com/en/news/286799449.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [While Everyone Chases AI, Pharma Keeps Getting Cheaper](https://longbridge.com/en/news/286650835.md)